

1 Brief Report

2

3 Differences in antibody kinetics and functionality between severe and mild SARS-
4 CoV-2 infections.

5 Running head: antibodies in severe and mild COVID-19

6 Ger Rijkers ^{1,2,6*}, Jean-Luc Murk ^{2*}, Bas Wintermans ^{1,3}, Bieke van Looy ¹, Marcel van
7 den Berge ⁴, Jacobien Veenemans ¹, Joep Stohr ², Chantal Reusken PhD⁵, Pieter van
8 der Pol ¹, and Johan Reimerink ⁵

9 ¹Department of Medical Microbiology and Immunology, Admiral De Ruyter Hospital,
10 4462 RA Goes, The Netherlands

11 ²Microvida, location St. Elisabeth-Tweesteden Hospital, 5022 GC Tilburg, The
12 Netherlands

13 ³Department of Medical Microbiology, Bravis Hospital, 4708 AE Roosendaal, The
14 Netherlands

15 ⁴Department of Internal Medicine, Admiral De Ruyter Hospital, 4462 RA Goes, The
16 Netherlands

17 ⁵WHO COVID-19 Reference Laboratory, Center for Infectious Disease Control,
18 National Institute for Public Health and the Environment (RIVM), 3721 MA Bilthoven,
19 The Netherlands

20 ⁶Science Department, University College Roosevelt, 4331 CB Middelburg, The
21 Netherlands

22

23 * contributed equally to this work

24

25

26

28 Abstract

29 We determined and compared the humoral immune response in severe, hospitalized
30 and mild, non-hospitalized COVID-19 patients. Severe patients (n=38) develop a
31 robust antibody response to SARS-CoV-2, including IgG and IgA antibodies. The
32 geometric mean 50% virus neutralization titer is 1:240. SARS-CoV-2 infected hospital
33 personnel (n=24), who developed mild symptoms necessitating leave of absence,
34 self-isolation, but not hospitalization, 75 % develop antibodies, but with low/absent
35 virus neutralization (60% < 1:20).

36 While severe COVID-19 patients develop a strong antibody response, mild SARS-
37 CoV-2 infections induce a modest antibody response. Long term monitoring will
38 show whether these responses predict protection against future infections.

39

40 Key words: SARS-CoV-2, COVID-19, antibody response, IgA antibodies, virus
41 neutralization.

42

43 Introduction

44 Severe acute respiratory syndrome virus 2 (SARS-CoV-2) which emerged in the
45 human population at the end of 2019 had reached pandemic proportions by March
46 2020 [1,2]. The host defense against this new member of the corona virus family will
47 depend on innate immunity, humoral and cellular immune responses, of yet unknown

48 relative importance [3,4]. For these reasons, level of protection and longevity of
49 protection cannot be established or predicted.

50 Similar to other respiratory viruses the primary diagnosis of COVID-19 is routinely
51 made by RT-PCR detection of SARS-CoV-2. As the sensitivity of molecular detection
52 relies on severity of illness, sample type and timing of sampling in the course of
53 infection [5,6], serology has important additional value to establish a recent infection
54 and to support patient care. It is therefore important to carefully determine the
55 kinetics, magnitude and functionality of the humoral immune response in COVID-19
56 patients with different disease severity.

57 Here, we have analyzed the type and functionality of the humoral immune response
58 of PCR-confirmed hospitalized COVID-19 patients, both ICU and non-ICU admitted,
59 and of non-hospitalized patients with mild disease. We performed a semi-
60 quantitative analysis of total Ig, IgG and IgA antibodies by ELISA as well as a
61 functional analysis by virus neutralization assays.

62 **Methods**

63 **Patients and blood sampling.**

64 Serum samples were collected from a prospective cohort of 38 RT-PCR-confirmed [7]
65 COVID-19 patients (Table 1) admitted to the Admiral de Ruyter Hospital in Goes, The
66 Netherlands in accordance with the local clinical procedures in the period March
67 2020 – May 2020. The presenting clinical symptoms included fever (n=17), coughing
68 (18), dyspnea (11), dizziness and/or confusion (4) and general malaise (6). Patients

69 were admitted to the hospital median 7 days (range 1-12) after onset of symptoms.

70 15 of 38 patients were admitted to the ICU. RT-PCR was always performed on the

71 first hospital day on nasopharyngeal swabs. Serial blood sampling (3 times per week)

72 was started a median 2 days (range 1-7) after positive RT- PCR.

73 The second cohort of 24 patients with mild COVID-19 disease consisted of hospital

74 personnel (both from clinical departments as well as laboratory departments) who

75 developed fever and/or coughing and/or dyspnea and were tested positive for SARS-

76 CoV-2 by RT- PCR. They were asked to maintain self-quarantine until symptoms

77 resolved. All of them were kept under control of their own GP and none of them

78 required hospitalization.

79 The study was performed in accordance with the guidelines for sharing of patient

80 data of observational scientific research in emergency situations as issued by the

81 Commission on Codes of Conduct of the Foundation Federation of Dutch Medical

82 Scientific Societies (<https://www.federa.org/federa-english>).

83

84 SARS-CoV-2 immunoassays.

85 The Wantai SARS-CoV-2 total antibody ELISA (Beijing Wantai Biological Pharmacy

86 Enterprise, Beijing, China; Cat # WS1096) was performed according to the

87 manufacturer's instructions [8]. This assay is an double-antigen sandwich ELISA using

88 the recombinant receptor binding domain antigen (RBD) of SARS-CoV-2 as antigen.

89 SARS-CoV-2 IgG and IgA antibodies were determined by ELISA using the beta-

90 version of the EUROIMMUN immunoassay kit (EUROIMMUN Medizinische
91 Labordiagnostika AG, <https://www.euroimmun.com>) according to the manufacturer's
92 protocol [8,9]. In this assay, wells are coated with recombinant structural protein (S1
93 domain) of SARS-CoV-2.

94

95 Corona virus microarray.

96 Sera were tested for the presence of IgG antibodies reactive with the four common
97 human coronaviruses hCoV-OC43, hCoV-HKU1, hCoV-NL63 and hCoV-229E S1
98 subunit antigens in a protein microarray essentially as described before [10].

99 Antibody titers were defined as the interpolated serum concentration that provokes a
100 response at 50% on a concentration-response curve between the minimum and
101 maximum signal processed with R 2.12.1 statistical software as described before [11].

102

103 SARS-CoV-2 Neutralization Assay

104 Sera were tested by a SARS-CoV-2-specific virus neutralization test (VNT) based on a
105 protocol described previously with some modifications [12]. Briefly, serial dilutions of
106 heat-inactivated samples (30 min 56°C) were incubated with 100 TCID₅₀ of SARS-
107 CoV-2 for 1h at 35°C. African green monkey (Vero-E6) cells were added in a
108 concentration of 2×10^4 cells per well and incubated for three days at 35°C in an
109 incubator with 5% CO₂. The VNT titer was defined as the reciprocal of the sample

110 dilution that showed a 50% (VNT50) or 90% (VNT90) protection of virus growth.

111 Samples with titers equal to 10 and higher were defined as SARS-CoV-2 seropositive.

112 Statistical Analysis

113 Categorical variables were described as frequency rates and percentages, and

114 continuous variables were described using geometric means, median, and

115 interquartile range values. Means for continuous variables were compared using

116 independent group t-tests. Categorical variables were compared using the Chi-square

117 test. All analyses were done in Excel with the data analysis toolpack. P-values of less

118 than 0.05 were considered statistically significant.

119

120 Results

121 A prospective cohort of 38 consecutive hospitalized COVID-19 patients (Table 1) was

122 monitored for development of anti-SARS-CoV-2 Ig, IgG and IgA antibodies. Within 2-

123 5 days post onset of symptoms, 4 patients already showed total Ig responses and a

124 steep increase in IgG ratio's (see also below and Figure 1a-c). Most patients

125 responded for IgG and IgA between day 10 and 15 (Figure 1b,c). The vast majority of

126 the hospitalized patients developed high levels of antibodies after 3-4 weeks: 100%

127 of patients had detectable (total)antibodies, 84% had detectable IgG antibodies, and

128 92% IgA antibodies.

129 Patients admitted to the ICU (n= 15) showed an antibody response similar to patients
130 in the general COVID-19 ward (n=23), with an IgG antibody ratio at day 14-21 of 9.9
131 ± 5.2 (ICU) and 8.7 ± 5.3 (ward), $p > 0.05$; IgA antibody ratio was ≥ 15 (ICU) and $13.6 \pm$
132 2.8 (ward), $p > 0.05$.

133 The functionality of the antibodies in the hospitalized cohort was assessed by VNT50
134 and VNT90 (Figure 1, panels d and e). In the first week upon onset of symptoms, 43%
135 of the patients had detectable VNT50 (median 22, range 10 to 640). At 21-28 days all
136 patients had detectable neutralizing antibody titers in the VNT50 with a median titer
137 of 226 (range 20 to 800). Median titer in the VNT90 was 50 (range <10-240).

138 As indicated above, 4 patients already showed high IgG levels (O.D. ratio > 5) and
139 even plateau levels of IgA antibodies early during the course of disease, i.e. within 10
140 days after onset of symptoms. To exclude cross-reactivity due to (recent) previous
141 infection with one of the four common coronaviruses (i.e hCoV-OC43, hCoV-NL63,
142 hCoV-HKU1 and hCoV-229E) in these so called "early IgA responders" antibodies
143 titers against these common CoVs were determined in two early responders (Figure
144 2a,b) and compared with those in two other COVID-19 patients (Figure 2c,d). We
145 found minimal and inconsistent fluctuations in IgG against the four common CoV
146 across all four patients indicating that the early IgA and total Ig anti-SARS-CoV-2
147 responses for some patients were not the result of cross-reactivity due to a previous
148 common CoV infection.

149 Next, we investigated the antibody responses in a cohort of hospital personnel who
150 had tested positive in the SARS-CoV-2 RT-PCR but had only experienced mild clinical
151 symptoms. 87% developed SARS-CoV-2 total antibodies by day 21-28, with a
152 significant lower titer than severe patients (GMT 4.9 and 17.3, respectively, $p < 0.001$).
153 The median titer in the VNT50 was 29 (range <10 to 640) and in VNT90 was 10 (range
154 <10 -12), both significantly lower than in severe patients (p values < 0.0001) (Figure 1,
155 panels d and e vs i and j). 33% of the mild patients remained negative for the
156 presence of virus neutralizing antibodies.

157

158 Discussion

159 Serial blood sampling of 38 severe (hospitalized) and 24 mild COVID-19 patients
160 allowed for detailed analysis of the kinetics and magnitude of the SARS-CoV-2
161 antibody response in patients with different levels of disease severity. At 2-4 weeks
162 after onset of symptoms detectable total, IgG and IgA antibodies were found in
163 100%, 86% and 94% of the severe patients, and 81%, 81%, 61% of the mild patients
164 respectively. Virus neutralizing activity was demonstrable in the vast majority of
165 severe patients (all at VNT50, 95% at VNT90) but only in 65% (VNT50) and 30%
166 (VNT90) in the mild patients. We did not find a significant difference in the kinetics,
167 magnitude, nor functionality of the response between hospitalized patients of
168 different disease severity (routine ward vs intensive care vs fatal outcome). This is in
169 accordance with findings in hospitalized SARS-CoV-1 patients [13]. It is however

170 possible that larger series of hospitalized patients with variable clinical outcome can
171 reveal differences in the nature and kinetics of the immune response, because our
172 sample size was limited.

173 Of 2 of our patients we had serum samples available from the period before onset of
174 COVID-19. As expected, total antibody, IgG and IgA anti-SARS-CoV-2 antibodies were
175 not demonstrable at that time.

176 Early responders (especially levels of IgG and IgA within 5 days after onset of
177 symptoms) were only observed in the hospitalized cohort and could have been due
178 to a prolonged pre-symptomatic period, or recall bias with respect to onset of
179 complaints [14]. Antibody levels against hCoV-OC43 and hCoV-HKUI in early
180 responder patients did not differ from other patients (data not shown) and antibody
181 levels against circulating coronaviruses did not change during the course of COVID-
182 19 in both very early and "normal" responders while SARS-CoV-2 directed IgA and
183 IgG levels did (Figure 2).

184 Two of our patients with severe disease who survived failed to show an IgG response
185 at day 21 after disease onset (although the total antibody assay was positive). Our
186 two IgG negative patients, 69 and 87 years of age, had persistently positive PCR test
187 results on respectively day 28 and day 37 after disease onset. Patients with an
188 inadequate IgG antibody response may exhibit prolonged viral shedding, and thus
189 longer periods of infectivity. Prolonged viral RNA shedding has been reported
190 previously [15], and further studies that include viral cultures are needed to

191 investigate the prolonged infectivity hypothesis. One (other) patient remained
192 negative for IgA antibodies, although this patient, as well as all others, had normal
193 serum IgA immunoglobulin levels (data not shown). Severe COVID-19 patients
194 remaining seronegative have also been reported by others (e.g. [6,8]). It can be
195 speculated that their antibody response is dominated by epitopes not represented in
196 the immunoassays we have used. Antibody testing against a more extensive array of
197 SARS-CoV-2 peptides will be required to address this possibility.

198 From our data it is clear that hospitalized COVID-19 patients mount a robust humoral
199 immune response against SARS-CoV-2, including antibodies with virus neutralizing
200 activity. Mild infections with SARS-CoV-2, with clinical symptoms not requiring
201 hospital admission, do show an antibody response but delayed in comparison to
202 severe patients and with minimal functional activity. Long term monitoring will be
203 required to determine whether these quantitative and qualitative parameters of the
204 humoral immune response predict protection against future infection.

205

206 **Acknowledgements**

207 We would like to thank all the personnel in the laboratory to make this evaluation
208 possible. Especially we would like to thank (in alphabetical order): Fion Brouwer, Gert-
209 Jan Godeke, Gabriel Goderski, Marieke Hoogerwerf, and Ilse Zutt.

210

211 References

212

- 213 1. Guan WJ, Ni ZY, Hu Y, China Medical Treatment Expert Group for Covid-19.
214 Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*
215 **2020** Feb 28. doi: 10.1056/NEJMoa2002032.
- 216 2. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*
217 **2020**; 91:157-60. doi: 10.23750/abm.v91i1.9397.
- 218 3. Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose
219 Novel Coronavirus Disease (COVID-19). *Clin Infect Dis* **2020** Mar 21. pii:
220 ciaa310. doi: 10.1093/cid/ciaa310.
- 221 4. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-
222 CoV-2. *JAMA* **2020**. doi:10.1001/jama.2020.8259
- 223 5. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-
224 19. *Lancet Infect Dis* **2020**;S1473-3099(20)30232-2. doi:10.1016/S1473-
225 3099(20)30232-2
- 226 6. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-
227 nCoV infected patients: implication of multiple shedding routes. *Emerg*
228 *Microbes Infect* **2020**; 9:386-89.
- 229 7. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus
230 (2019-nCoV) by real-time RT-PCR. *Euro Surveill* **2020**;25. doi: 10.2807/1560-
231 7917.

- 232 8. Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome
233 coronavirus 2–specific antibody responses in coronavirus disease 2019
234 patients. *Emerg Infect Dis.* **2020** Jul . <https://doi.org/10.3201/eid2607.200841>
- 235
236 9. Lassaunière R, Frische A, Zitta B et al. Evaluation of nine commercial SARS-
237 CoV-2 immunoassays. medRxiv preprint doi:
238 <https://doi.org/10.1101/2020.04.09.20056325>
- 239
240 10. Reusken C, Mou H, Godeke G J, et al. Specific serology for emerging human
241 coronaviruses by protein microarray. *Euro Surveill* **2013**;18(14):pii=20441.
242 <https://doi.org/10.2807/1560-7917.ES2013.18.14.20441>
- 243
244 11. Koopmans M, de Bruin E, Godeke GJ, et al. Profiling of humoral immune
245 responses to influenza viruses by using protein microarray. *Clin Microbiol*
246 *Infect* **2012**; 18:797-807.
- 247
248 12. Algaissi A, Hashem AM. Evaluation of MERS-CoV Neutralizing Antibodies in
249 Sera Using Live Virus Microneutralization Assay. *Methods Mol Biol*
250 **2020**;2099:107-16.
- 251
252 13. Chan KH, Cheng VC, Woo PC, et al. Serological responses in patients with
253 severe acute respiratory syndrome coronavirus infection and cross-reactivity
254 with human coronaviruses 229E, OC43, and NL63. *Clin Diagn Lab Immunol*
255 **2005**; 12:1317-21. doi:10.1128/CDLI.12.11.1317-1321.2005

256

257 14. Ho MS, Chen WJ, Chen HY, et al. Neutralizing antibody response and SARS

258 severity. *Emerg Infect Dis* **2005**;11:1730-37. doi:10.3201/eid1111.040659


259

260 15. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult

261 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

262 *Lancet* **2020**;395(10229):1038

263



264

265

266 Figure 1. Quantitative and qualitative antibody response against SARS-CoV-2 in


267 severe (panels a-e) and mild COVID-19 patients (panels f-j).

268 Shown are total (panels a and f), IgG (panels b and g), IgA (panels c and h) antibody

269 levels as well as virus neutralization titer at 50% neutralization (panels d and i) and

270 90% neutralization (e and j).

271 The horizontal line in the middle of each box indicates the geometric mean, the top
272 and bottom borders of the box mark the 75th and 25th percentiles, the whiskers
273 above and below the box indicate the range. Outliers, with values > 1.5 the
274 interquartile range, are indicated with individual dots.



275
276 Figure 2. Antibody levels against circulating corona viruses during the course of
277 COVID-19 disease. Each panel (a-d) represents a single patient. IgG and IgA SARS-
278 CoV-2 antibodies displayed by blue and red circles, respectively, and expressed as
279 O.D. ratio values on the left Y-axis. hCoV 229E (□), HKU1 (◇), NL63 (△), and OC43
280 (○) IgG antibody titers are shown as open symbols and expressed as titers.

281

282 Table 1. Patient characteristics

Variable	Evaluable	Median (range) / n (%)	Intensive care		p-value
			No (n = 23)	Yes (n = 15)	
Age (years)	38	70 (38 - 87)	71 (38 - 87)	68 (56 - 80)	0.37 ¹
Male gender	38	26 (68)	14 (61)	12 (80)	0.21 ²
Any comorbidities	38	26 (68)	13 (56)	13 (87)	0.11 ²
Diabetes mellitus	38	4 (11)	4 (17)	0 (0)	0.14 ²
Hypertension	38	13 (34)	8 (35)	5 (33)	0.79 ²
Coronary heart disease	38	8 (21)	6 (26)	2 (13)	0.59 ²
COPD	38	10 (26)	4 (17)	6 (40)	0.24 ²
Body Mass Index	31	27 (19-41)	28 (19-41)	25 (22-27)	0.14 ¹
Mortality	38	6 (16)	4 (17)	2 (13)	0.90 ²


283 ¹ p-value of two-sided Student T-test

284 ² p-value of Chi-square test


285 COPD: Chronic Obstructive Pulmonary Disease

286





Severe (hospitalized)



Mild (non-hospitalized)



SARS-CoV-2 IgG (●) and IgA (○) O.D. ratio



days after onset of symptoms